| Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. P McLaughlin, AJ Grillo-López, BK Link, R Levy, MS Czuczman, ... Journal of clinical oncology 16 (8), 2825-2833, 1998 | 3663 | 1998 |
| Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma ML Wang, S Rule, P Martin, A Goy, R Auer, BS Kahl, W Jurczak, ... New England Journal of Medicine 369 (6), 507-516, 2013 | 1896 | 2013 |
| Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised … SV Rajkumar, S Jacobus, NS Callander, R Fonseca, DH Vesole, ... The lancet oncology 11 (1), 29-37, 2010 | 1214 | 2010 |
| Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results ML Wang, KA Blum, P Martin, A Goy, R Auer, BS Kahl, W Jurczak, ... Blood, The Journal of the American Society of Hematology 126 (6), 739-745, 2015 | 470 | 2015 |
| Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma KS Robinson, ME Williams, RH van der Jagt, P Cohen, JA Herst, ... Journal of Clinical Oncology 26 (27), 4473-4479, 2008 | 435 | 2008 |
| Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia AD Kennedy, PV Beum, MD Solga, DJ DiLillo, MA Lindorfer, CE Hess, ... The Journal of Immunology 172 (5), 3280-3288, 2004 | 413 | 2004 |
| Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study A Goy, R Sinha, ME Williams, S Kalayoglu Besisik, J Drach, ... Journal of clinical oncology 31 (29), 3688-3695, 2013 | 404 | 2013 |
| Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab TA Davis, CA White, AJ Grillo-Lopez, WS Velasquez, B Link, DG Maloney, ... Journal of Clinical Oncology 17 (6), 1851-1851, 1999 | 398 | 1999 |
| Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study JW Friedberg, P Cohen, L Chen, KS Robinson, A Forero-Torres, ... Journal of Clinical Oncology 26 (2), 204-210, 2008 | 396 | 2008 |
| Bendamustine is effective therapy in patients with rituximab‐refractory, indolent B‐cell non‐Hodgkin lymphoma: results from a multicenter study BS Kahl, NL Bartlett, JP Leonard, L Chen, K Ganjoo, ME Williams, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2010 | 335 | 2010 |
| Postibrutinib outcomes in patients with mantle cell lymphoma P Martin, K Maddocks, JP Leonard, J Ruan, A Goy, N Wagner-Johnston, ... Blood, The Journal of the American Society of Hematology 127 (12), 1559-1563, 2016 | 293 | 2016 |
| The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes PV Beum, AD Kennedy, ME Williams, MA Lindorfer, RP Taylor The Journal of Immunology 176 (4), 2600-2609, 2006 | 281 | 2006 |
| MHC class I–associated phosphopeptides are the targets of memory-like immunity in leukemia M Cobbold, H De La Peña, A Norris, JM Polefrone, J Qian, AM English, ... Science translational medicine 5 (203), 203ra125-203ra125, 2013 | 253 | 2013 |
| Rearrangement of the chromosome 11 bcl-1 locus in centrocytic lymphoma: analysis with multiple breakpoint probes ME Williams, TC Meeker, SH Swerdlow | 231 | 1991 |
| Rituximab extended schedule or re-treatment trial for low–tumor burden follicular lymphoma: Eastern Cooperative Oncology Group protocol E4402 BS Kahl, F Hong, ME Williams, RD Gascoyne, LI Wagner, JC Krauss, ... Journal of Clinical Oncology 32 (28), 3096-3102, 2014 | 228 | 2014 |
| From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades SH Swerdlow, ME Williams Human pathology 33 (1), 7-20, 2002 | 215 | 2002 |
| Natural killer-like T-cell lymphomas: aggressive lymphomas of T-large granular lymphocytes WR Macon, ME Williams, JP Greer, RD Hammer, AD Glick, RD Collins, ... Blood 87 (4), 1474-1483, 1996 | 210 | 1996 |
| European Lymphoma Task Force (ELTF): report of the workshop on mantle cell lymphoma (MCL) E Zucca, H Stein, B Coiffier, C Bastard, Y Bastion, F Berger, G Brittinger, ... Annals of oncology 5 (6), 507-511, 1994 | 199 | 1994 |
| Chromosome 11q13 amplification in head and neck squamous cell carcinoma: association with poor prognosis SD Meredith, PA Levine, JA Burns, MJ Gaffey, JC Boyd, LM Weiss, ... Archives of Otolaryngology–Head & Neck Surgery 121 (7), 790-794, 1995 | 175 | 1995 |
| Chromosome 11Q13 amplification in head and neck squamous cell carcinoma ME Williams, MJ Gaffey, LM Weiss, SP Wilczynski, E Schuuring, ... Archives of Otolaryngology–Head & Neck Surgery 119 (11), 1238-1243, 1993 | 171 | 1993 |
